Policies have been proposed to remove obstacles to prescribing buprenorphine to people with opioid use disorder. But a larger barrier to treatment expansion is cultural: physicians and institutions fail to treat substance use disorders as the chronic diseases they are.
Funding and Disclosures
Disclosure forms provided by the author are available at NEJM.org.
This article was published on May 8, 2021, at NEJM.org.
Print Subscriber? Activate your online access.